Perrigo
Headquartered in Ireland, Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products and receives royalties from Multiple Sclerosis drug Tysabri.
In 2013 it acquired Irish pharma company Elan.
Financial Data
-
31st Dec 18 Source: CRO
- €4.2 billion turnover
-
€255.3 million
profit - 10,400 employees
-
31st Dec 17 Source: CRO
- €4.1 billion turnover
-
€229.2 million
profit - 10,400 employees
- 4 more years available »
Ranking
By Turnover
(€4.2 billion)- 27th in Top Companies
- 6th in Health
- 5th in Pharma
By Employees
(10,400)- 21st in Top Companies
- 4th in Health
- 4th in Pharma
-
- 10,400
- €4.2 billion
Employees
- Murray S. Kessler CEO/Managing Director
Latest News
- May 20 Amarin to seek European approval for heart drug Vascepa
- May 20 Markets spooked by US-China trade row
- May 20 US to signal approval of $26.5bn T-Mobile US and Sprint merger
- May 20 Intel gets green light for $4bn development at Leixlip
- May 20 Hong Kong ‘worried’ over short-term impact of US-China trade war